Hyperbaric Oxygen Therapy for Lung Transplantation
Disorder Related to Lung Transplantation, Central Airway Stenosis, Airway Exudative Plaques
About this trial
This is an interventional treatment trial for Disorder Related to Lung Transplantation focused on measuring Hyperbaric Oxygen, Lung Transplantation, Central Airway Stenosis, Airway Exudative Plaques, Hyperbaric Oxygen Therapy, Post-Lung Transplantation, Airway Ischemia, Endobronchial Biopsy, Bronchoscopy
Eligibility Criteria
Inclusion Criteria:
- Post-lung transplant patient
- Extensive exudative plaques at 1 month bronchoscopy
- No sign of airway improvement, or showing worsening of plaques at follow-up bronchoscopy 2-3 weeks after 1 month bronchoscopy.
Exclusion Criteria:
- Use of mechanical ventilation with fraction of inspired oxygen(FiO2) greater than 40%
- Use of extracorporeal membrane oxygenation
- Use of inhaled nitric oxide
- Presence of pneumothorax
- Pregnancy
- Inability to provide informed consent
Sites / Locations
- Duke University Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Hyperbaric Oxygen, Airway Biopsy
No Hyperbaric Oxygen, Airway Biopsy
The hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 (2 ATA) once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician. During standard bronchoscopies, an endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.
No hyperbaric oxygen therapy administered, but lung biopsy still completed during standard post-lung transplant bronchoscopies. An endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.